about
Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational researchOvarian function following targeted anti-angiogenic therapy with bevacizumabInvestigational drugs for the treatment of cervical cancer.Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed.Human papillomavirus oncoproteins induce a reorganization of epithelial-associated γδ T cells promoting tumor formation.
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Bevacizumab for the treatment of cervical cancer.
@en
type
label
Bevacizumab for the treatment of cervical cancer.
@en
prefLabel
Bevacizumab for the treatment of cervical cancer.
@en
P2093
P2860
P50
P1476
Bevacizumab for the treatment of cervical cancer
@en
P2093
Franco Alessandri
Mario Valenzano Menada
Pier Luigi Venturini
Stuart Rundle
Valentina Ghirardi
P2860
P304
P356
10.1517/14712598.2016.1145208
P407
P577
2016-01-01T00:00:00Z